Nanobody developer joins investors and Big Pharma business development leaders as oncology dealmaking confronts a historic patent cliff.
PHP Biotech International Inc., a privately held biotechnology company developing nanobody therapeutics designed to be effective against aggressive solid tumors, today announced its sponsorship of the 3rd Annual Oncology Venture, Innovation & Partnering Summit, taking place Oct. 19–20, 2026, in Cambridge, Massachusetts.
The summit, produced by Cambridge Healthtech Institute, convenes oncology investors, pharmaceutical executives, and emerging biotech founders around a single question: how breakthrough cancer science gets funded, partnered, and brought to patients. PHP Biotech is both a sponsor of and a participant in the program, joining the conversation at the moment its lead candidate completes its core preclinical package.
“Being a Sponsor of this summit reflects PHP Biotech’s favorable view of the event and a deliberate choice about where we spend our time,” said Robert Gahagen, Chief Executive Officer of PHP Biotech. “The people attending have a vested interest in exploring, funding and developing novel oncology assets. We are there to showcase how our nanobody technology delivers a first-in-kind method of action targeting aggressive solid tumors that today have limited alternatives to meaningfully extend life expectancy.”
The timing is pointed. Leading pharmaceutical companies are staring down the largest patent cliff in decades, and are openly rethinking R&D investment priorities, licensing structures, and the criteria that drive acquisition decisions. Business development and external innovation leaders scheduled to address those themes at the summit include Carla Bauer, PhD, Director, Search & Evaluation, Business Development & Licensing at Merck; Polly Brown, Vice President, Head of Business Development, Oncology R&D at AstraZeneca; Ildiko Csiki, MD, PhD, Head of External Innovation, Oncology at Pfizer; Xiaodong Zhang, PhD, Director, Business Development Search & Evaluation, Oncology & Hematology at Novartis; and Michal Preminger, PhD, MBA, Chief Executive Officer of BioMed X Venture Labs and former regional head of J&J Innovation.
PHP Biotech arrives with an asset built for that discussion. Its lead candidate, PHP53-nb, is a first-in-class humanized camelid nanobody that genetically incorporates 3-NAntC, that selectively targets a variety of solid tumors. The nanobody exploits uPAR as an internalization trigger, leveraging the increased cell-surface expression of this receptor in tumors harboring mutated or nonfunctional p53. Once the nanobody enters the cancer cell through endocytosis, it escapes the endocytic vesicles and becomes available in the cytoplasm, where it drives proteotoxic and ER stress, reactivates p53-wt-like signaling, disrupts mitochondrial function, and ultimately commits the cell to a programmed apoptotic death.
Mutations in TP53, the gene encoding p53, occur in roughly half of all human cancers and in a higher share of the most aggressive tumors. PHP Biotech’s preclinical work centers on several aggressive tumor types including triple-negative breast cancer, pancreatic, lung and colo-rectal which all carry poor prognosis for patients today.
“Size is key to functionality,” said Patrícia Bezerra, PhD, Head of Research & Development at PHP Biotech. “At roughly 17 kilodaltons, our nanobody is about one-tenth the mass of a conventional monoclonal antibody and where the cancer-fighting peptide is genetically encoded within the protein itself rather than chemically attached through a linker. This design is what enables an originally unstable peptide reach the tumor cell intact and access its intracellular targets.”
The delivery architecture, designated GEN01-AD, is proprietary to PHP Biotech and is designed to carry bioactives beyond 3-NAntC, opening combination and multi-specific approaches. On the manufacturing side, gene-optimized plasmids expressed in CHO cells have raised yields more than 100-fold from early laboratory scale, from approximately 5 mg/L to 693 mg/L, with further gains expected from clone selection and process development.
PHP Biotech plans to complete its core preclinical package, covering efficacy, mechanism, toxicity, characterization, and biodistribution, soon in 2026, with first-in-human Phase I studies anticipated in 2027, subject to regulatory review. The company is actively working with qualified CRO and CDMO partners and is pursuing collaboration with pharma entities that see synergies with their existing pipelines.
Forward-Looking and Investigational Status
PHP53-nb is an investigational biologic and has not been approved by the U.S. Food and Drug Administration or any other regulatory authority. It is not available as a treatment outside authorized clinical research. Preclinical findings do not guarantee clinical benefit. Statements regarding planned preclinical completion, anticipated clinical timelines, and partnering activity are forward-looking and subject to scientific, regulatory, and financing risks. This release is informational and is not medical advice.
###
For more information about PHP Biotech, contact the company here:
PHP Biotech
Robert Gahagen
(888) 739-6972
contact@phpbiotech.com
550 Reserve St. STE 190
Southlake, TX 76092
